Dylipidémies Thérapeutiques Flashcards

1
Q

Statines ( mécanisme )

A

Inhibiteur HMG-CoA réductase

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

Ezétimibe (mécanisme)

A

Inhibiteur absorption intestinale cholestérol (transporteur NP1CL1)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

Résines (mécanisme)

A

Diminue réabsorption intestinale AB

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

Inhibiteurs PCSK9 (mécanisme)

A

Augmente recyclage du R LDL

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

Fibrates (mécanisme)

A

Activateurs PPAR-alpha

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

AG oméga 3 (mécanisme)

A

Diminue production VLDL

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

Statines (effets)

A

↘️20-55%LDL/↘️5-15%TG/↗️5%HDL

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

Ezétimibe (effets)

A

↘️20%LDL

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

Résines

A

↘️10-30%LDL/↗️25%TG(attention)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

Inhibiteurs PCSK9 (effets)

A

↘️50-70%LDL

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

Fibrates (effets)

A

↘️30-50%TG/↘️10-25%LDL/↗️10-15%HDL

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

AG oméga 3 (effets)

A

↘️10-30%TG

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

CI tous hypolipémiants

A

Grosses et alaitement

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

CI Statines

A

Atcd rhabdomyolyse sous Statines/affection hépatique/transaminases 3N

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

CI Ezétimibe

A

Affection hépatique/TA>3N

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

CI Colestyramine

A

IHC/cholestase/constipation chronique

17
Q

CI fibrates

A

IHC/IRC

18
Q

Intéractions AVK

A

Statines, Ezétimibe, fibrates ↗️ effet anticoagulant

19
Q

Intéraction colestyramine

A

↘️absorption intestinale des médicaments

20
Q

Intéraction pamplemousse

A

Augmente biodisponibilité ( inhibiteur CYP3A4)

21
Q

Risque association statine et fibrate

A

Majore risque rhabdomyolyse

22
Q

Association statine+gemfibrozil(fibrate)

A

Contre indiquée

23
Q

Prescription statine->contrôle dans les 2-3 mois ?

A

Evaluation lipidique à jeun/ASAT ALAT hépat